Vertex Pharmaceuticals Incorporated (VRTX)
POSITIVEFondamental
70
Prix
$553.22
Capitalisation boursière
$138.79B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Vertex develops medicines that treat the genetic root cause of cystic fibrosis, a disease that had no such treatment before Vertex's drugs existed, and its CFTR-modulator therapies now reach most eligible patients worldwide. The company has begun diversifying its pipeline beyond cystic fibrosis with a gene-edited cell therapy for sickle cell disease and beta thalassemia, developed jointly with CRISPR Therapeutics, and a new non-opioid medicine for acute pain that targets a completely different market.
Comment l'entreprise gagne de l'argent
Nearly all revenue comes from direct sales of chronic-use medicines, mostly distributed through a small number of large US pharmacy wholesalers and specialty pharmacies rather than sold to patients directly. Because cystic fibrosis is a lifelong condition, patients who start on a Vertex therapy typically stay on it, or on its successor, for years, which gives revenue an annuity-like quality once a drug is launched and adopted.
Chiffre d'affaires par segment
The company's flagship cystic fibrosis therapy, treating the majority of eligible patients worldwide and still the overwhelming majority of revenue.
A newer, once-daily cystic fibrosis therapy intended to eventually succeed TRIKAFTA/KAFTRIO; still in early launch.
Includes CASGEVY, a one-time gene-edited cell therapy for sickle cell disease and beta thalassemia, the new pain medicine JOURNAVX, and older cystic fibrosis drugs.
Royalty and other minor revenue streams outside product sales.
Avantage concurrentiel
Brevets et licences · LargeVertex is essentially the only company that treats the genetic cause of cystic fibrosis rather than just its symptoms, a position protected by patents projected to run to 2037 for TRIKAFTA/KAFTRIO and 2039 for ALYFTREK. No rival has brought a competing CFTR modulator to market despite years of trying, which makes this one of the more durable moats in pharmaceuticals today.
Ce qui stimule la demande
DéfensifCystic fibrosis is a genetic, lifelong condition, so patients need treatment regardless of the economic environment, and demand does not meaningfully rise or fall with consumer spending or business cycles. What can move results instead is drug pricing and reimbursement policy, and the pace at which new therapies like CASGEVY and JOURNAVX are adopted by physicians and payers.
Principaux risques
- Revenue concentrated in the CF franchise — TRIKAFTA/KAFTRIO and ALYFTREK together make up roughly nine-tenths of revenue. Any safety, efficacy or competitive setback in cystic fibrosis therapy would affect nearly the whole business at once.
- Distributor concentration — McKesson and Accredo together handled 34% of gross product revenue in 2025, so a dispute or disruption with either distributor could delay a meaningful share of collections.
- Slow uptake of new launches — CASGEVY, a complex one-time gene therapy, reached only 64 patients in all of 2025, showing how slowly a genuinely novel treatment can be adopted even when clinically effective.
- Drug pricing policy — US and international reforms aimed at lowering drug prices could compress net pricing on Vertex's therapies regardless of their clinical value or patent protection.
Concentration des clients
Les principaux clients représentent 34% du chiffre d'affaires
Two distributors, McKesson Corporation and Accredo Health Group, accounted for 22% and 12% of gross product revenue in 2025, respectively. These are pharmacy wholesalers serving many patients, not end customers, but their financial health still matters for collections.
Les arguments en faveur
Buyers point to a near-monopoly in treating the genetic cause of cystic fibrosis with patent protection running past 2037, a strong balance sheet funding three new launches that diversify beyond cystic fibrosis, and demand for chronic-disease treatment that does not depend on the economic cycle.
Les arguments contre
Sellers note that roughly nine-tenths of revenue still comes from one franchise, that the newest launches are ramping slowly with CASGEVY reaching only 64 patients all year, and that two distributors handle over a third of gross product sales.
Written by the editors, published on 18 août 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$12.59B
12 derniers mois (au 30/06/2026)
Résultat net
$4.41B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$3.19B
Capitaux propres totaux
$18.67B
Passif total
$6.98B
Ratio de liquidité général
3.19
Couverture des intérêts
313.78
Dette/EBITDA
0.45
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$437.43
Prix actuel
$553.22
Marge de sécurité
-26.5%
Fourchette de juste valeur
$332.11 - $542.74
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
31.89
ROE
21.2%
Ratio P/B
6.85
P/FCF
36.56
Marge brute
86.0%
ROIC
16.1%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
16.1%
WACC
7.9%
ROIC − WACC
+8.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (20)
- EPS shows upward trend
- Price CAGR 22.23%
- ROIC 16.1%
- Gross Margin 86.0%
- Debt/Equity ratio
- Operating Margin 38.0%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 23.3%
- Revenue Growth 5Y 14.1%
- Analyst Consensus 81% Buy
- Earnings Quality (OCF/NI) 0.97
- Share Dilution 0.2%
- Net Margin Trend 35.0% vs 31.9%
- Piotroski F-Score 6/9
Échoué (6)
- P/FCF 36.56
- P/B Ratio 6.85
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.0%
- PEG Ratio 3.71
Indisponible (1)
- Dividend Payout NaN%
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Modérée : certain écart entre profits et trésorerie
Dilution du capital
Le nombre d'actions est stable
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman | 69 |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, President & Director | 52 |
| Mr. Charles F. Wagner Jr. | Executive VP, COO & CFO | 57 |
| Mr. Amit K. Sachdev J.D. | Executive VP & Chief Patient and External Affairs Officer | 57 |
| Dr. Ourania Tatsis Ph.D. | Executive VP and Chief Regulatory & Quality Officer | 55 |
| Dr. Carmen Bozic M.D. | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 62 |
| Ms. Kristen C. Ambrose CPA | Senior VP & Chief Accounting Officer | 48 |
| Dr. Mark Bunnage D.Phil | Executive VP & Chief Scientific Officer | 56 |
| Ms. Susie Lisa C.F.A. | Senior Vice President of Investor Relations | - |
| Ms. Joy Liu J.D. | EVP, Chief Legal Officer & Corporate Secretary | 47 |
Risque d'audit
4
Risque du conseil
5
Risque de rémunération
6
Risque droits des actionnaires
6
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for VRTX, sourced from Markets Gazette.
- 6/12/2026POSITIVEHere's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
An investment of $1000 in Vertex Pharmaceuticals (VRTX) a decade ago would have yielded a substantial return, growing to approximately $7,240 today. This represents an impressive annualized return of over 22%. The company's consistent performance over the past ten years underscores its strong growth trajectory and effective drug development pipeline. For investors, this historical performance highlights VRTX as a potentially robust long-term holding, demonstrating its capacity to generate significant value through innovation and market success in the biopharmaceutical sector.
- 6/11/2026POSITIVEVertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Vertex Pharmaceuticals announced positive data from its pediatric study of CASGEVY, a gene-editing therapy for sickle cell disease and beta-thalassemia. The data demonstrate consistent and sustained clinical benefits in young patients, including significant reductions in vaso-occlusive crises and transfusion requirements. This reinforces the therapy's efficacy and safety profile in a crucial demographic. For investors, these findings suggest strong long-term growth potential for CASGEVY and solidify Vertex's leadership in rare blood disorder treatments, potentially leading to increased market share and revenue.
- 5/25/2026POSITIVEIf You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
An investment of $100 in Vertex Pharmaceuticals (VRTX) twenty years ago would have grown to approximately $10,500 today, representing a staggering 10,400% return. This performance significantly outpaced the broader market, highlighting the company's exceptional growth trajectory and successful drug development pipeline. Vertex's focus on transformative medicines for serious diseases, particularly cystic fibrosis, has been a key driver of its stock appreciation. Investors who held VRTX through this period have benefited immensely from the company's innovation and market leadership.
- 3/30/2026POSITIVEIf You Invested $1000 In Vertex Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today
An investment of $1000 in Vertex Pharmaceuticals (VRTX) 15 years ago would have yielded a substantial return, illustrating the company's strong long-term performance. While specific figures are not provided in the title, the implication is significant wealth creation for shareholders. This historical performance suggests robust growth driven by successful drug development, strategic execution, and market demand for its therapies. Investors considering VRTX should note its track record as an indicator of potential future value, though past performance is not indicative of future results.
- 3/16/2026POSITIVEIs Vertex Pharmaceuticals Heading to $600?
Vertex Pharmaceuticals is nearing a potential new product approval, fueling speculation about its stock price reaching the $600 mark. While specific details of the product and its approval timeline are not disclosed, the anticipation of a new revenue stream and market expansion is a significant catalyst. Investors are closely watching for regulatory updates, as a successful approval could lead to substantial revenue growth and solidify Vertex's position in its therapeutic areas. This development suggests strong underlying fundamentals and a positive future outlook for the company.
- 3/15/2026POSITIVEThis Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
An investor divested $5 million in Vertex Pharmaceuticals (VRTX) shares, a company specializing in cystic fibrosis therapies. Despite this sale, the stock's impressive 118% surge over the past year, and a recent nearly 90% year-over-year gain as per the latest filing, suggests continued underlying strength. The sale, representing a small fraction of the company's market cap, may be attributed to portfolio rebalancing or tax-loss harvesting rather than a fundamental bearish view. Investors should focus on VRTX's robust pipeline and consistent growth trajectory, which remain strong indicators for future performance.
- 3/12/2026POSITIVEIf You Invested $1000 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
An investment of $1000 in Vertex Pharmaceuticals (VRTX) 20 years ago would have yielded a substantial return, growing to approximately $14,500 today. This hypothetical scenario highlights the significant long-term growth potential of VRTX stock, driven by its consistent performance and innovation in the biotechnology sector. Investors who held VRTX over the past two decades have benefited from the company's advancements in treating serious diseases like cystic fibrosis, underscoring the value of strategic, long-term investments in promising pharmaceutical companies.
- 2/22/2026NEUTRALCould Vertex Stock Help Turn $100,000 Into $1 Million by 2036?
A speculative analysis explores the long-term growth potential of Vertex Pharmaceuticals, posing a hypothetical scenario of turning a $100,000 investment into $1 million by 2036. This tenfold return scenario prompts investors to evaluate the company's innovation pipeline, market position, and future earnings prospects. However, the article is not based on concrete news or a specific catalyst but is framed as a forward-looking valuation exercise. The cautionary note that "even a great stock has a ceiling" serves as a reminder of inherent risks and valuation limits. The piece encourages reflection on the long-term investment thesis for Vertex without providing new information likely to impact the stock's price in the short term.
via Markets Gazette